Pfizer paid about $55 million to resolve allegations that Wyeth, which it bought in 2009, used CME to promote Protonix for off-label use, the Justice Department said.
Companies can improve their performance by blending hard numbers, like outcomes and cost savings, with softer messaging that centers on payer and patient relationships, a PricewaterhouseCoopers report argues.